Dutasteride improves male pattern hair loss in a randomized study in identical twins

Journal of Cosmetic Dermatology

Volumn 6, Issue 1, 2007, Pages 9-13

  Stough, Dow ^a  

^a The Dermatology Clinic   (United States)

Author keywords

Androgenetic alopecia; Dutasteride; Identical twins

Indexed keywords

DUTASTERIDE; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HAIR GROWTH; HUMAN; LIBIDO; MALE; MALE TYPE ALOPECIA; MEDICAL PHOTOGRAPHY; MONOZYGOTIC TWINS; PATIENT SATISFACTION; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SELF EVALUATION; SIDE EFFECT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ALOPECIA; AZASTEROIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FOLLOW-UP STUDIES; HAIR; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PATIENT SATISFACTION; PROBABILITY; PROSPECTIVE STUDIES; REFERENCE VALUES; RISK FACTORS; TESTOSTERONE 5-ALPHA-REDUCTASE; TREATMENT OUTCOME; TWINS, MONOZYGOTIC;

EID: 33847789989     PISSN: 14732130     EISSN: 14732165     Source Type: Journal    
DOI: 10.1111/j.1473-2165.2007.00297.x     Document Type: Article

References (26)

1. Norwood OT. Male pattern baldness: Classification and incidence. South Med J 1975; 68: 1359-65.
2. Rhodes T, Girman CJ, Savin RC et al. Prevalence of male pattern hair loss in 18-49 year old men. Dermatol Surg 1998; 24: 1330-2.
3. Hamilton JB. Male hormone stimulation is prerequisite and an incitant in common baldness. Am J Anat 1942; 71: 451-80.
4. Hamilton JB. Patterned loss of hair in man: Types and incidence. Ann N Y Acad Sci 1951; 53: 708-28.
5. Kroemer HC. What is the right statistical measure of twin concordance (or diagnostic reliability and validity?). Arch Gen Psychiatry 1997; 54: 1121-4.
6. Car AB, Marlin NG, Whitfield JB. Usefulness of the co-twin control design in investigations as exemplified in a study of effects of ascorbic acid on laboratory test results. Clin Chem 1981; 27: 1469-70.
7. Christian JC, Kang KW. Efficiency of human monozygotic twins in studies of blood lipids. Metabolism 1972; 21: 691-9.
8. Zaslavskaia RM, Zolotaia RD, Lil'in ET. "Partner control"method of twin studies in evaluating the hemodynamic effects of nonachlazine. Farmakol Toksikol 1981; 44: 357-60.
9. Carr AB, Einstein R, Lai LY, Martin NG, Starmer GA. Vitamin C and the common cold: Using identical twins as controls. Med J Aust 1981; 2: 411-2.
10. Gormley GJ. Finasteride: A clinical review. Biomed Pharmacother 1995; 49: 319-24.
11. Harris G, Azzolina B, Baginsky W et al. Identification and selective inhibition of an isozyme of steroid 5α-reductase in human scalp. Proc Natl Acad Sci USA 1992; 89: 10787-91.
12. Vermeulen A, Giagulli VA, De Schepper P, Buntinx A. Hormonal effects of a 5α-reductase inhibitor (finasteride) on hormonal levels in normal men and in patients with benign prostatic hyperplasia. Eur Urol 1991; 20 (Suppl. 1): 82-6.
13. McConnell JD, Wilson JD, George FW, Geller J, Pappas F, Stoner E. Finasteride, an inhibitor of 5α-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J Clin Endocrinol Metab 1992; 74: 505-8.
14. Dallob AL, Sadick NS, Unger W et al. The effect of finasteride, a 5α-reductase inhibitor, on scalp skin testosterone and dihydrotestosterone concentrations in patients with male pattern baldness. J Clin Endocrinol Metab 1994; 79: 703-6.
15. Drake L, Hordinsky M, Fiedler V et al. The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia. J Am Acad Dermatol 1999; 41: 550-4.
16. Roberts JL, Fiedler V, Imperato-McGinley J et al. Clinical dose ranging studies with finasteride, a type 2 5α-reductase inhibitor, in men with male pattern hair loss. J Am Acad Dermatol 1999; 41: 555-63.
17. Kaufman KD, Olsen EA, Whiting D et al. Finasteride in the treatment of men with androgenetic alopecia. J Am Acad Dermotol 1998; 39: 578-88.
18. Leyden J, Dunlap F, Miller B et al. Finasteride in the treatment of men with frontal male pattern hair loss. J Am Acad Dermatol 1999; 40: 930-7.
19. McClellan KJ, Markham A. Finasteride: A review of its use in male pattern hair loss. Drugs 1999; 57: 111-26.
20. Canfield D. Photographic documentation of hair growth in androgenetic alopecia. Dermatol Clin 1996; 14: 713-21.
21. Kaufman K, Binkowitz B, Savin R, Canfield D. Reproducibility of global photographic assessments of patients with male pattern boldness in a clinical trial with finasteride. J Invest Dermatol 1995; 104: 659.
22. Van Neste D, Fuh V, Sanchez-Pedreno P et al. Finasteride increases anagen hair in men with androgenetic alopecia. Br J Dermatol 2000; 143: 804-10.
23. Barber BL, Kaufman KD, Kozloff RC, Girman CJ, Guess HA. A hair growth questionnaire for use in the evaluation of therapeutic effects in men. J Dermatol Treat 1998; 9: 181-6.
24. Kaufman KD. Finasteride male pattern hair loss study group. Long-term (5 years) multinational experience with finasteride in the treatment of men with androgenetic alopecia (male pattern hair loss). Eur J Dermatol 2002; 12: 38-49.
25. Stough DB, Rao NA, Kaufman KD, Mitchell C. Finasteride improves male pattern hair loss in a randomized study in identical twins. Eur J Dermatol 2002; 12: 32-7.
26. Olsen EA, Hordinsky M, Whiting D et al. The importance of dual 5α-reductase inhibition in the treatment of male pattern hair loss: Results of a randomized placebo-controlled study of dutasteride versus finasteride. J Am Acad Dermatol 2006; 55 (6): 1014-23.